HO-1 (haem oxygenase-1) is a ubiquitously expressed inducible enzyme degrading haem to CO, biliverdin and Fe 2 + . Its activation reduces oxidative stress in cells and inhibits inflammation, both due to removal of haem and because of the biological activity of HO-1 products. CO may act similarly to NO, activating soluble guanylate cyclase and elevating cGMP production. It inhibits platelet aggregation, reduces leucocyte adhesion, decreases apoptosis and lowers the production of some pro-inflammatory cytokines. Biliverdin is converted into bilirubin by biliverdin reductase, and both compounds are potent antioxidants, free radical scavengers and inhibitors of the complement cascade. Iron ions can be potentially toxic, increasing the generation of hydroxyl radicals, but simultaneous induction of ferritin and activation of the Fe-ATPase iron transporter protects cells from oxidative stress. Importantly, basal and induced expression of HO-1 is very variable in the human population because of the highly polymorphic (GT)n fragment in the promoter, which may have clinical relevance. The recognized roles of HO-1 are far beyond cytoprotection. The enzyme is important in the regulation of cell proliferation, differentiation and apoptosis. Its activity improves neovascularization, attenuates inflammation and modulates the immune response, thereby influencing carcinogenesis, wound healing, transplant survival and the progression of cardiovascular diseases. Recent results indicate that HO-1 may also act through the regulation of microRNAs, which suggests a much broader involvement of HO-1 in the modulation of cell functions and offers a potential explanation for some well-known activities whose mechanism has hitherto been unclear.
Scheme 1 Scheme of HO-1 activity
Haem is released from the haem proteins (i.e. haemoglobin, myoglobin and cytochrome). HO-1 catalyses the reaction of its degradation, yielding three biologically active products: CO, biliverdin and Fe 2 + . Biliverdin is subsequently reduced to bilirubin by BVR. Expression of HO-1 is induced by pro-oxidative stimuli.
HO-1 is a 32 kDa protein localized in microsomes; however, it has also been demonstrated to be present in caveoli [8] , mitochondria [9] and nuclei [3] (Figure 1 ). Of the two HO isoforms, designated HO-1 and HO-2 and encoded by two distinct genes [10] [11] [12] , only HO-1 is an inducible enzyme. Its expression is upregulated in response to cellular stress and by prooxidative stimuli, such as haem [13] , UV light [14] , LPS (lipopolysaccharide) [15] , hydrogen peroxide [16] , cobalt protoporphyrin [17] , heat shock [18] , heavy metals [13] , pro-inflammatory cytokines [19] , NO [20] , ethanol and prostaglandins [21] . The so-called HO-3 form, described in rats, turned out to be a processed pseudogene derived from an HO-2 transcript [22] .
The basal level of HO-1 is rather weak in mammalian tissues, apart from the liver and spleen where the gene is strongly expressed [10] . It has been proven to possess cytoprotective, anti-apoptotic, pro-angiogenic and antiinflammatory features, which are achieved due to the biological activity of the products of haem degradation, alone or in combination, and due to the protein itself (schemes of the biological activities of HO-1 products are shown in [23] ) (Scheme 1).
The most comprehensively studied product, CO, is a signalling molecule that modulates many physiological processes. CO, similarly to NO, was shown to activate soluble guanylate cyclase [24] and thereby inhibit platelet aggregation [25] , decrease adhesion of leucocytes [26] , cause blood vessel relaxation [27] and suppress apoptosis of cells [28] . HO-1-derived CO was also demonstrated to stimulate blood vessel formation [29] . It induces VEGF (vascular endothelial growth factor) synthesis [22, 30, 31] , stimulates proliferation of endothelial cells [32, 33] , mediates SDF-1 (stromal-cell-derived factor-1)-driven angiogenesis [34] and is important for neovascularization during wound healing [35] . Moreover, CO has been recognized as a neurotransmitter [36] , again resembling NO activity. Other studies proved CO to exert anti-inflammatory effects. Thus CO inhibits the synthesis of pro-inflammatory cytokines such as IL-1β (interleukin-1β), TNF (tumour necrosis factor) and MIP-1β (macrophage inflammatory protein-1β), and upregulates the expression of anti-inflammatory proteins, such as IL-10. These effects are possibly mediated via p38 MAPKs (mitogen-activated protein kinases) [37] .
Importantly, there is a reciprocal feedback between HO-1 and CO. It was demonstrated, that HO-1-derived CO induces the expression of HO-1 via the survival transcription factor Nrf2 (nuclear factor-erythroid 2-related factor 2)-dependent pathway [38, 39] . Such a mechanism was shown to occur in human umbilical vein endothelial cells subjected to ER (endoplasmic reticulum) stress, which triggers an unfolded protein response. Both exogenous and endogenous CO prevented ER-stress-driven endothelial cell apoptosis by inhibiting the pro-apoptotic transcription factor CHOP [C/EBP (CCAAT/enhancer-binding protein)-homologous protein] [38] . Consistently, induction of apoptosis by ER stress was shown to be increased in the presence of HO-1 inhibitors [40] , and CHOP expression correlated negatively with the presence of Nrf2 [41] . Thus HO-1 in tandem with CO might be regarded as a strong natural defence against vascular diseases associated with ER stress, and this protective advantage of the HO-1/CO system may be of clinical significance.
One of the most elegant examples demonstrating the beneficial effects of HO-1-derived CO is its significance in malaria suppression. This disease is caused by Plasmodium infection of red blood cells, leading to haemolysis, haemoglobin release and, as a consequence to the generation of free haem, a molecule toxic to the cells. At this stage, HO-1 is up-regulated, haem is catabolized and CO is generated. The protective effect of CO is achieved by its binding to haemoglobin released from the infected cells. In consequence, the appearance of free haem is prevented, thus attenuating the deleterious effects of malaria [42] .
The second product of haem degradation, biliverdin, is subsequently converted into bilirubin by BVR (biliverdin reductase). These two bile pigments are a very important part of an antioxidative protection system, especially meaningful in the extracellular fluids. Bilirubin is able to scavenge hydroxyl radicals, singlet oxygen and superoxide anions, and is recycled back to biliverdin [43, 44] . The cytoprotective activity of biliverdin/bilirubin is based on inhibition of lipid and protein peroxidation [45] . Apart from antioxidative properties, bilirubin also possesses anti-inflammatory potential. It attenuates leucocyte rolling, decreasing Pand E-selectin expression, and inhibits the complement cascade [46, 47] .
Finally, the release of Fe 2 + from degraded haem may actually lead to protection of the cell from oxidative stress, even though free Fe 2 + ions are toxic due to the ability to interact with cellular oxidants to generate hydroxyl radicals [48] . In this case, the cytoprotective effect of the HO-1 product is indirect: Fe 2 + potently stimulates the expression of ferritin, the iron-storage protein that has known antioxidative properties. Moreover, it activates an iron pump, Fe-ATPase, decreasing the free iron content inside the cells [49, 50] .
The protection of cells against oxidative stress had been ascribed exclusively to the enzymatic function of HO-1. However, transfection of U937 cells with the protein lacking catalytic activity still sheltered them through mechanisms involving up-regulation of catalase and glutathione peroxidase expression and an increase in GSH content [51] . This observation, described in 2002 by Hori et al. [51] , suggested that the HO-1 protein itself was involved in cellular signalling and regulation of gene transcription. Indeed, several years later it was reported that, upon stimulation with hypoxia or haem, HO-1 is cleaved, localizes in the nucleus and influences the expression of cytoprotective genes [3] . HO-1, in contrast with BVR, is not a transcription factor, so the regulation of gene expression seems to be indirect. Importantly, the nuclear transfer of HO-1 leads to the loss of its enzymatic activity ( Figure 1 ).
HO-1 GENE PROMOTER POLYMORPHISM
There are numerous reports recognizing the gene encoding HO-1 as one of the most important cytoprotective genes, whose expression is induced as an adaptive response to pro-oxidative stimuli. The question is whether the experiments utilizing HO-1-knockout mice, revealing the devastating consequences of HO-1 absence, can be translated to humans, as human HO-1 deficiency almost never occurs.
The answer is, indeed, positive. Although HO-1 deficiency is extremely rare, the level of HO-1 expression can be variable within the human population, because the promoter of HMOX1 (human HO-1 gene) is highly polymorphic. It contains a stretch of microsatellite DNA with GT repeats, ranging from 11 to 40, located within the regulatory sequence approximately 250 bp upstream of the transcripton start site [52] . As purinepyrimidine alternating sequences assume a Z-DNA conformation, the (GT) n polymorphism was supposed to affect transcription and modulate the basal and induced HO-1 expression [52, 53] . Such a possibility is potentially meaningful, since HO-1 generation is regulated mostly at the transcriptional level [54] .
Figure 2 HO-1 promoter polymorphism
The HO-1 promoter is polymorphic, containing various numbers of GT dinucleotides. The number of GT repeats influences HO-1 gene expression and activity, thus modulating the cell function.
The distribution of alleles with different (GT) n lengths is bimodal within the human population, with the most frequent variants containing 23 and 30 repeats. In the majority of reports, the threshold values defining 'shorter' and 'longer' alleles have been chosen arbitrarily, not on the basis of functional characteristics [52, [55] [56] [57] [58] . However, it appears consistent throughout the published studies that longer (GT) n sequences are associated with diminished HO-1 expression. Indeed, transfection of aortic smooth muscle cells with reporter plasmids containing allelic variants of the HMOX1 promoter confirmed that constructs with longer (GT) n repeats drove a lower transcriptional activity [59] . Importantly, a recent study clearly demonstrated that the number of GT repeats modulated HO-1 expression and activity in human endothelium [55] . Moreover, differences in HO-1 inducibility influenced cell functions. The endothelial cells with short dinucleotide sequences (n 25) displayed a more favourable GSH/GSSG ratio, were more resistant to oxidative stress, proliferated faster in response to VEGF treatment and produced lower concentrations of pro-inflammatory cytokines [55] (Figure 2) .
The promoter polymorphism-dependent variability in HO-1 activity can be of clinical relevance. It has been found to be associated mostly with the risk of cardiovascular disorders (the role of HO-1 in cardiovascular physiology and pathology is described comprehensively in [29] ). For example, the HO-1 expression level was shown to be significantly diminished in diabetic patients with longer dinucleotide repeats [60] , whereas only the promoters with short (GT) n sequences were activated in response to oxidative stimuli [59, 61] . Furthermore, short (GT) n repeats were associated with low levels of inflammatory markers [62, 63] , whereas long dinucleotide repeats were associated with a greater extent of lipid peroxidation in serum [59] .
There are several papers demonstrating that the subpopulations of patients undergoing angioplasty and coronary stenting are less vulnerable to restenosis development if they carry short alleles [57, 58, 63, 64] . On this basis, the polymorphism of the HMOX1 promoter can be regarded as an independent risk factor for angiographic complications [57] . However, a report by Tiroch et al. [65] describing the large group of subjects does not support the clinical association of the HMOX1 promoter polymorphism with restenosis after coronary stenting, so this relationship seems to demand further investigation.
Similar unclear effects of HMOX1 promoter polymorphism have been obtained in the case of atherosclerosis progression. The increase in CAD (coronary artery disease) occurrence was demonstrated in a screened Chinese population with Type 2 diabetes carrying long fragments of (GT) n repeats [59] . In agreement with this study, Kaneda et al. [66] showed a reduced incidence of CAD in hyperlipidaemic, diabetic and smoking Japanese patients with short (GT) n sequences. However, in contrast with Asian populations, these results were not reproduced in Caucasians, as Endler et al. [67] reported no significant association of the HMOX1 genotype with CAD.
It is noteworthy that HO-1 can protect transplants from injury [68, 69] , and the expression of antioxidative genes by a graft was shown to be crucial to improve its survival [68, 70] . Therefore the association of the HMOX1 promoter polymorphism with transplantation outcome was also examined. As in cases of restenosis and atherosclerosis development, the results concerning the genotype of (GT) n sequences and graft survival are contradictory. The studies were carried out predominantly on renal transplantations, but also on heart grafts. There are reports showing that organs with short (GT) n repeats survive better and are less susceptible to tissue injury [71, 72] . On the other hand, a recent study revealed no influence of HMOX1 genotype on kidney survival, although a significant association was observed when considering normal and deteriorated graft function [73] . Similar results regarding kidney survival and the presence of (GT) n sequences were also described by another group [74] . Finally, no influence of the HMOX1 promoter polymorphism on renal survival was reported in chronic kidney disease [75] .
It was also hypothesized that patients with low HO-1 expression or receiving the heart transplant from a donor with a decreased level of HO-1 are more likely to reject the transplant or develop CAD [76, 77] . Again, the investigation of a larger group did not reveal any influence of HMOX1 promoter (GT) n polymorphism on patient survival, development of CAD or graft rejection [77] .
In summary, results concerning a protective effect of short, more active, alleles of the HMOX1 promoter on the development of restenosis or atherosclerosis as well as on the outcome of transplantation are contradictory and require further exploration. It seems that allelic variants of the HMOX1 promoter may modulate HO-1 expression and activity, predominantly in response to pro-oxidative stimuli, and influence various cell functions and disease states, at least in some groups of patients. However, large-scale clinical analyses do not always confirm these associations, indicating that the significance of (GT) n polymorphism may be related to patient ethnicity or may play a role only in some specific conditions.
IMMUNOMODULATORY EFFECTS OF HO-1
HO-1 is commonly regarded as an anti-inflammatory and immunosuppressive protein. Numerous papers demonstrated this stress-responsive enzyme to attenuate inflammation and to modulate immune response both in vitro and in vivo (reviewed in [78] ). The most compelling results come from the investigations carried out in HO-1-knockout mice, which have strong abnormalities in immune regulation and develop chronic inflammatory reactions [79] . Splenocytes isolated from these animals produced higher amounts of Th1-type cytokines, such as IL-1β, IL-6, IFNγ (interferon γ ) and TNFα, in response to LPS stimulation in comparison with wildtype cells [80] . Moreover, the serum level of IgM was significantly increased in HO-1-deficient mice compared with wild-type counterparts [80] . Accordingly, transgenic mice overexpressing HO-1 specifically in the lung were protected from the development of pulmonary inflammation induced by hypoxia [81] .
Previous evidence suggests that HO-1 exerts immunomodulatory effects, mainly through modulation of T-cell responses. The induction of HO-1 suppresses the activation and proliferation of CD4 + T-cells via COmediated inhibition of IL-2 secretion [82] . It has also been shown that exposure of CD3-activated T-cells to low concentrations of CO exerted an antiproliferative effect dependent on the inhibition of caspase 8 expression and activity [83] . Accordingly, HO-1 inhibition by SnMP (tin mesoporphyrin) induced maturation, proliferation and activation of naive T-cells [84] .
Another
very important subpopulation of T cells influenced by HO-1 are Tregs (regulatory T-cells). It is noteworthy that CD4
+ CD25 + Tregs express HO-1 constitutively [85] and pharmacological inhibition of HO-1 suppresses human Treg function in vitro [86] . Moreover, the suppressive activity of CD4 + CD25 + FoxP3 + (where Fox is forkhead box) Tregs was impaired in response to SnMP treatment [84] . However, it was also reported that Treg development and activity are not altered in HO-1-deficient mice [87] . Apart from innate immune responses, HO-1 was also reported to regulate autoimmunity. In a model of experimental encephalomyelitis, myeloid-restricted HO-1-deficient mice were more prone to develop disease with more severe clinical outcomes, which were abrogated by exogenous IFNβ administration [88] .
Another indication that HO-1 can be involved in the regulation of immune response is a beneficial influence of HO-1 on allograft protection from acute and chronic rejection [89] [90] [91] . A study by George et al. [92] showed that HO-1 activity in antigen-presenting cells is significant for Treg-mediated suppression, which can lead to prolonged transplant survival. Apart from Tregs, HO-1 was also shown to modulate immunosuppressive properties of MSCs (mesenchymal stem cells). Injection of MSCs delayed heart allograft rejection, but simultaneous inhibition of HO-1 induced it, completely reversing the protective effect of MSC administration [93] . Finally, the possible mechanism of the anti-inflammatory action of HO-1 is an inhibition of antigen-presenting cells [94] .
The anti-inflammatory potential of HO-1 is usually ascribed to CO. This molecule was demonstrated to suppress expression of pro-inflammatory cytokines in macrophages, possibly by modulation of the p38 MAPK [37] or JNK (c-Jun N-terminal kinase) signalling pathways and the transcription factor AP-1 (activator protein-1) [95] . HO-1 and CO were also shown to inhibit activation of NF-κB (nuclear factor κB) [96, 97] and to suppress T-cell proliferation [82] . On the other hand, CO up-regulates production of anti-inflammatory mediators, such as IL-10 [37] . Importantly, HO-1-knockout mice that underwent ischaemic lung injury were rescued by inhaled CO. CO inhibited the induction of PAI-1 (plasminogen-activator inhibitor-1) in macrophages, a critical mediator of pulmonary microvascular thrombosis [98] . The protective effects of CO in vasculature are usually regulated by soluble guanylate cyclase [98] ; however, some reports show soluble-guanylate-cyclaseindependent effects of CO [28, 99] .
Thus the clinical significance of immunomodulatory activities of HO-1 can be focused on transplant rejection and therapy of autoimmune disease. On the other hand, inhibition of HO-1 may lead to an augmented immune response in the case of cancer treatment.
HO-1 IN CANCER
The protective effects of HO-1, predominantly reported in cardiovascular and renal disorders, unfortunately may also apply to cancer cells. A growing number of papers demonstrate that HO-1 may modulate tumour induction and influences tumour growth and metastasis. Importantly, HO-1 level is usually elevated in cancer tissues, depending on the type of tumour (pancreatic cancer [100] , glioblastoma [101] , hepatoma [102] , adenocarcinoma [103] , melanoma [104] or prostate cancer [105] ). Within the tumours, HO-1 can be localized both in infiltrating leucocytes, especially macrophages, and/or in cancer cells [101, 104] . Its expression is further up-regulated in response to therapy, which leads to augmented oxidative stress [100, 106] . On this basis, the cytoprotective, anti-inflammatory and anti-apoptotic properties of HO-1 can be regarded as disadvantageous in cancer (reviewed in [23] ). Also the pro-angiogenic activity of HO-1 can be a drawback, since tumours with a volume of more than 1-2 mm 3 require expansion of the vasculature, and the vascular system is an exquisite way to metastasize.
Because of the potentially promoting role of HO-1 in cancer progression, suppression of HO-1 activity is considered to be a possible antitumour approach. Indeed, inhibition of HO-1 by administration of ZnPPIX (zinc protoporphyrin IX; a pharmacological inhibitor of HO-1 activity) was shown to suppress the growth of lung cancer [107] , sarcoma [108] and hepatoma [102] .
Facilitating the progression of existing tumours does not preclude the protective effects of HO-1 against carcinogens and a reduced probability of tumour initiation. Thus, hinting at a role for the HMOX1 promoter polymorphism in cancers, the patients lacking the short (GT) n sequences and, as a consequence, with a lower level of HO-1 activity are more prone to tumour development [23] . Accordingly, the presence of a long allele was recognized to be related to the increased risk of oral squamous cell carcinoma in patients chewing areca [109] . Moreover, long (GT) n repeats were more frequent in a group of patients with lung adenocarcinoma in comparison with a control group, and the risk of cancer development for a long allele versus a non-long allele was increased within the male smokers [110] . The opposite relationship was found in the case of melanoma, where short (GT) n sequences were more frequent in patients with tumours in comparison with healthy subjects [111] . This observation is in agreement with the effects of HO-1 on melanoma development in an animal model [105] . Thus the association of the HMO1 promoter polymorphism with the risk of cancer development seems to be tumour-type-dependent.
HO-1 IN THE METABOLIC SYNDROME
The metabolic syndrome is a medical disorder characterized by visceral obesity, raised blood pressure, increased inflammation and an abnormal lipid profile, with a reduced level of HDL (high-density lipoprotein) cholesterol. It is one of the major risk factor for diabetes and cardiovascular complications. Keeping in mind that HO-1 serves a protective role in the vascular system, the question of the role for HO-1 in the metabolic syndrome has recently been raised. To address this issue, lean and obese mice were treated with the potent HO-1 inducer CoPPIX (cobalt protoporphyrin IX) and its influence on the regulation of adiposity was assessed. HO-1 induction affected fat distribution and metabolic function in obese mice dependent on gender. In contrast with male obese mice, female obese animals, despite CoPPIX administration, gained weight at a rate similar to controls. However, HO-1 induction normalized blood pressure and increased serum adiponectin. Moreover, it caused a decrease in plasma levels of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNFα. In both male and female obese animals, an expansion of smaller more insulinsensitive adipocytes was observed. These changes were regulated via the increase in adipocyte HO-1 protein level and were ascribed to adiponectin up-regulation [112] . Taken together, pharmacological or gene-therapy-based induction of HO-1 might be regarded as a promising tool to improve insulin sensitivity and attenuate other obesity-mediated metabolic disorders.
HO-1 IN CELL DIFFERENTIATION
The number of papers regarding the influence of HO-1 on various physiological and pathological processes started to grow very quickly in the mid-1990s. The significance of HO-1 in cell protection, proliferation, migration and apoptosis, as well as in the immune response, cancer development, angiogenesis, the cardiovascular system and renal function, have been well recognized.
Several investigations have demonstrated the potential role of HO-1 in cell differentiation ( Table 1) . Some of them show the involvement of HO-1 in bone cell (both osteoblast and osteoclast) maturation. The report by Zwerina et al. [113] demonstrated that induction of HO-1 inhibits osteoclastogenesis both in vitro and in vivo, leading to a loss of bone resorption. Similar results were obtained in the case of chronic periodontitis, where the HO-1 pathway was shown to provide a defence mechanism against substance P-induced osteoclastic differentiation in periodontal ligament cells [114] . Of importance, HO-1 up-regulation was also demonstrated to exert the same effect on osteoblasts, the main cells forming a bone, and the mechanism of this process was ascribed to all HO-1-activity products [115] . HO-1 activation was also reported to regulate the differentiation of adipocytes. MSCs cultured in proadipogenic medium and treated with CoPPIX showed an impaired adipose differentiation in comparison with untreated cells [116, 117] . Consistently, adipogenesis was inhibited in cells treated with sofalcone, a compound up-regulating HO-1 expression [118] . In addition, enzymatic activity of HO-1 attenuates the differentiation of haemopoietic stem cells [119] and immune cells, such as monocyte-derived dendritic cells [120] , Kupffer cells [121] or monocytes [122] , confirming the role for this pathway in the regulation of the immune response.
Our recent experiments demonstrated that genetic or pharmacological activation of HO-1 inhibited the differentiation of murine muscle precursors, and that these effects were mediated, at least in part, by modulation of the microRNA transcriptome, especially the musclespecific microRNA [123] . This implies a much broader involvement of HO-1 in the regulation of cell functions and offers a potential explanation for some well-known activities whose mechanism has been hitherto unclear.
The cell types whose differentiations were induced by HO-1 expression are less numerous. For example, CoPPIX stimulation of human dental pulp cells revealed up-regulation of several odontoblastic markers, and differentiation of these cells was inhibited by a CO scavenger, iron chelator, HO-1 inhibitor and siRNA (small interfering RNA) HO-1 silencing, indicating the involvement of haem degradation products in the maturation of dental pulp cells [124] . Also, human enterocytes treated with SnPPIX showed decreased differentiation in comparison with control cells [125] . It should be stressed, however, that the role of HO-1 as a regulator of cell differentiation has been appreciated only recently and the underlying mechanisms have still not been elucidated.
CONCLUSIONS
HO-1 is a multitask enzyme playing an important role in the regulation of cell proliferation, differentiation, oxidative status and apoptosis, thereby influencing immune response, inflammatory reaction or angiogenesis. Thus its significance is much wider than only haem elimination. HO-1 is one of the most strongly induced genes in cells exposed to stressful conditions, and hundreds of experiments have shown that the products of HO-1 activity are involved in the maintenance of cell homoeostasis. The importance of HO-1 in cardiovascular diseases and cancer progression has been commonly accepted, especially when taking into consideration the variability of HO-1 in the human population, resulting from HO-1 promoter polymorphism. The intriguing question when assigning new directions of research concerns the significance of microRNAs in HO-1-mediated effects. The following years should provide more data elucidating the complex interactions of HO-1 with this elaborate gene-regulatory system. 
